Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02928510 · ClinicalTrials.gov registry record
Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma
A clinical trial, sponsored by Jonsson Comprehensive Cancer Center.
- Terminated
- Registry status
- 1
- Enrollment target
NCT02928510 is a clinical trial that was terminated before completion, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 1 participants.
The verdict
NCT02928510 was terminated before completion, sponsored by Jonsson Comprehensive Cancer Center.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
This research trial studies the mechanisms of idelalisib-associated diarrhea in patients with chronic lymphocytic leukemia, indolent non-hodgkin lymphoma, or small lymphocytic lymphoma that has come back after a period of improvement. The cancer treatment drug idelalisib triggers diarrhea in some patients. Studying stool, blood, and tissue samples in the lab from patients who are given idelalisib may help doctors learn more about the side effects and may help to treat them in future patients.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Colonoscopy
- OTHER Laboratory Biomarker Analysis
- DRUG Idelalisib
- PROCEDURE Colposcopic Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2018-06-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02928510
The ClinicalTrials.gov registry entry for NCT02928510 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT02928510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02928510 about?
NCT02928510 is a clinical study titled "Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma". This research trial studies the mechanisms of idelalisib-associated diarrhea in patients with chronic lymphocytic leukemia, indolent non-hodgkin lymphoma, or small lymphocytic lymphoma that has come back after a period of improvement. The cancer treatment drug idelalisib triggers diarrhea in some pa...
What is the current status of trial NCT02928510?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2016-02-01. Estimated completion is 2018-06-05.
What interventions are being tested in trial NCT02928510?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Colonoscopy (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Idelalisib (DRUG), Colposcopic Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02928510?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.